<DOC>
	<DOCNO>NCT00003478</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell deliver radioactive tumor-killing substance radioactive iodine without harm normal cell . PURPOSE : This randomized phase I/II trial study side effect , best way give , best dose radiolabeled monoclonal antibody see well work treat patient primary brain tumor .</brief_summary>
	<brief_title>Radiolabeled Monoclonal Antibody Therapy Treating Patients With Primary Brain Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine one two delivery technique ( bolus injection versus microinfusion ) provide great distribution volume iodine I 131 antitenascin monoclonal antibody 81C6 ( I 131 MAb 81C6 ) administer intratumorally patient newly diagnose recurrent malignant primary brain tumor . - Determine maximum tolerate dose I 131 MAb 81C6 deliver intratumorally patient . - Evaluate efficacy I 131 MAB 81C6 deliver intratumorally patient . OUTLINE : This randomize , dose-escalation study . Patients randomize receive iodine I 131 antitenascin monoclonal antibody 81C6 ( I 131 MAb 81C6 ) one two delivery technique first , crossover receive antibody technique 3 day later . Each patient receive therapeutic dose efficient method . Both method deliver via stereotactically-placed intralesional catheter . - Arm I : Bolus injection method - Arm II : Microinfusion delivery method Cohorts 3-6 patient receive escalate dos I 131 MAb 81C6 , dose escalation occur separately arm . After 10 patient enrol best method administration determine , subsequent patient receive I 131 MAb 81C6 method , maximum tolerate dose ( MTD ) determine . The MTD define dose 2 6 patient experience dose-limiting toxicity . Patients newly diagnose tumor effective conventional therapy exists , malignant glial tumor , treat external beam radiotherapy within 4 month I 131 MAb 81C6 infusion . Patients recurrent tumor receive therapy unless tumor progress . Patients follow 4 , 8 , 16 , 24 week every 12 week one year . PROJECTED ACCRUAL : At least 10 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove newly diagnose recurrent primary intracranial WHO grade III IV glioma Reactivity tumor cell 81C6 demonstrate immunohistology either polyclonal rabbit antibody monoclonal mouse antibody Radiographic evidence single lesion MRI CT scan No great 2 5 cm No cerebral herniation syndrome Midline brain shift le 0.5 cm PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1000/mm^3 Platelet count great 100,000/mm^3 Hemoglobin great 10 g/dL Hepatic : Bilirubin le 1.5 mg/dL Alkaline phosphatase less 1.5 time normal SGOT le 1.5 time normal Renal : Creatinine le 2.0 mg/dL Other : Not pregnant nursing Fertile patient must use effective contraception No allergy iodine local anesthetic PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent autologous bone marrow transplant Chemotherapy : No 1 prior conventional phase II chemotherapy regimen No prior phase I chemotherapy regimen At least 4 week since prior chemotherapy No concurrent systemic chemotherapy Endocrine therapy : Corticosteroids allow must stable dose least 1 week Radiotherapy : At least 3 month since radiotherapy site measurable disease nervous system , unless evidence progression Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult brain stem glioma</keyword>
	<keyword>adult medulloblastoma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult ependymoblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>